Direct determination of diclofenac in pharmaceutical formulations containing B vitamins by using UV spectrophotometry and partial least squares regression

dc.creatorSena, MM
dc.creatorChaudhry, ZF
dc.creatorCollins, CH
dc.creatorPoppi, RJ
dc.date2004
dc.date43770
dc.date2014-11-20T06:12:39Z
dc.date2015-11-26T16:07:40Z
dc.date2014-11-20T06:12:39Z
dc.date2015-11-26T16:07:40Z
dc.date.accessioned2018-03-28T22:56:19Z
dc.date.available2018-03-28T22:56:19Z
dc.identifierJournal Of Pharmaceutical And Biomedical Analysis. Pergamon-elsevier Science Ltd, v. 36, n. 4, n. 743, n. 749, 2004.
dc.identifier0731-7085
dc.identifierWOS:000225530100008
dc.identifier10.1016/j.jpba.2004.08.001
dc.identifierhttp://www.repositorio.unicamp.br/jspui/handle/REPOSIP/62596
dc.identifierhttp://www.repositorio.unicamp.br/handle/REPOSIP/62596
dc.identifierhttp://repositorio.unicamp.br/jspui/handle/REPOSIP/62596
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1266187
dc.descriptionThis work proposes a simple and rapid analytical procedure for determination of diclofenac (DCF) in the presence of B vitamins, based on UV measurements and partial least squares (PLS). The interference of thiamine (THI) and pyridoxine (PYR) were modelled using an experimental design constructed in the ranges of 10-50 mumol l(-1) for DCF and THI and 15-75 mumol l(-1) for PYR. The procedure was repeated at five different pH values (between 3 and 6) and the best results were observed at pH 5, presenting a root mean square error of prediction (RMSEP) of 0.80 mumol l(-1) for DCF. The procedure was successfully applied to simultaneous determination of DCF, THI and PYR in synthetic mixtures and in a pharmaceutical formulation that contains a simple excipient (lactose). For determination of a more complex formulation that contains 15 different substances in the excipient, including some UV absorbing ones, the procedure was only able to determine DCF, since the excipient interferences disturbed THI and PYR predictions. Figures of merit, such as selectivity, analytical sensitivity, limit of detection and precision were determined for the DCF prediction model and the determinations were verified by an independent method, HPLC. (C) 2004 Elsevier B.V. All rights reserved.
dc.description36
dc.description4
dc.description743
dc.description749
dc.languageen
dc.publisherPergamon-elsevier Science Ltd
dc.publisherOxford
dc.publisherInglaterra
dc.relationJournal Of Pharmaceutical And Biomedical Analysis
dc.relationJ. Pharm. Biomed. Anal.
dc.rightsfechado
dc.rightshttp://www.elsevier.com/about/open-access/open-access-policies/article-posting-policy
dc.sourceWeb of Science
dc.subjectdiclofenac
dc.subjectthiamine
dc.subjectpyridoxine
dc.subjectcomplex B vitamins
dc.subjectmultivariate calibration
dc.subjectPLS
dc.subjectNonsteroidal Antiinflammatory Drugs
dc.subjectPerformance Liquid-chromatography
dc.subjectMultivariate Calibration
dc.subjectSpectrofluorometric Determination
dc.subjectAcetylsalicylic-acid
dc.subjectInjection-analysis
dc.subjectAcute Lumbago
dc.subjectSodium
dc.subjectElectrophoresis
dc.subjectCyclodextrin
dc.titleDirect determination of diclofenac in pharmaceutical formulations containing B vitamins by using UV spectrophotometry and partial least squares regression
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución